Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kringle PharmaTSE:4884 -2.46%40 PB Ratio is 2.47 as of Jul. 23, 2026, which is 27% above its 10-year median of 1.94. GuruFocus rates TSE:4884 with a GF Score™ of 40/100 and a GF Value™ of 円489.64 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,230 Biotechnology companies, Kringle Pharma ranks better than 54.47% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-23), Kringle Pharma's share price is 円317.00. Kringle Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was 円128.18. Hence, Kringle Pharma's PB Ratio of today is 2.47.
The historical rank and industry rank for Kringle Pharma's PB Ratio or its related term are showing as below:
TSE:4884'
s PB Ratio Range Over the Past 10 Years
Min: 0.82 Med: 1.94 Max: 4.33
Current: 2.48
During the past 8 years, Kringle Pharma's highest PB Ratio was 4.33. The lowest was 0.82. And the median was 1.94.
TSE:4884's PB Ratio is ranked better than 54.47% of 1230
companies
in the Biotechnology industry
Industry Median: 2.82
vs TSE:4884: 2.48
During the past 12 months, Kringle Pharma's average Book Value Per Share Growth Rate was -45.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -28.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -20.60% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Kringle Pharma was 106.00% per year. The lowest was -28.90% per year. And the median was -15.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Kringle Pharma PB Ratio Related Terms
Kringle Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Kringle Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kringle Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kringle Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kringle Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Kringle Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Kringle Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Kringle Pharma (TSE:4884) has a PB Ratio of 2.47 as of Jul. 23, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kringle Pharma and its competitors. This is 27% above median its historical median of 1.94. Over the past decade, Kringle Pharma's PB Ratio has ranged from 0.82 to 4.33. According to the industry distribution chart, Kringle Pharma ranks #560 out of 1230 companies in the Biotechnology industry, placing it in the top 45.5%.
Is Kringle Pharma's PB Ratio too high?
Kringle Pharma's current PB Ratio of 2.47 is 27% above median its 10-year median of 1.94. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 4.33. The Biotechnology industry median PB Ratio is 2.82. Kringle Pharma's value of 2.47 is 12.4% below this industry median. Based on the distribution chart, Kringle Pharma ranks #560 out of 1230 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kringle Pharma has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kringle Pharma ranks #560 out of 1230 companies for PB Ratio. This puts Kringle Pharma in the upper half of its industry. The industry median PB Ratio is 2.82. Kringle Pharma's value of 2.47 is 12.4% below this benchmark. Historically, Kringle Pharma's own PB Ratio has ranged from 0.82 to 4.33 over the past decade. While the company's 10-year median is 1.94 vs. the industry median of 2.82, Kringle Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kringle Pharma's current PB Ratio of 2.47 is 12.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kringle Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kringle Pharma's current PB Ratio is 2.47, which is 27% above median its own 10-year median of 1.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円489.64, compared to a current price of 円317.00 — trading 35.3% below its estimated fair value. The current PB Ratio is 2.47, which is 27% above median its 10-year median of 1.94 and 12.4% below the Biotechnology industry median of 2.82. Kringle Pharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current PB Ratio is 2.47 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kringle Pharma (TSE:4884) Overvalued in 2026?
Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued.
The current stock price of 円317.00 is trading 35.3% below its estimated GF Value™ of 円489.64.
GuruFocus considers Kringle Pharma to be Possible Value Trap.
Key valuation signals for TSE:4884:
PB Ratio: 2.47 (27% above median its 10-year median of 1.94)
GF Value™: 円489.64 vs. price of 円317.00 (35.3% below fair value)
Industry Position: 12.4% below the Biotechnology median (#560 of 1230)
No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
40GF Score
Get the complete analysis for TSE:4884
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4884 has been successfully added to your 
